These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28815894)

  • 21. Important role of translational science in rare disease innovation, discovery, and drug development.
    Pariser AR; Gahl WA
    J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S804-7. PubMed ID: 25029971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations.
    Babiker HM; Davis L; Larson K; Placencia C; Swensen C; Tenneti P; Lim M; Cañamar R; Curtis J; Castillo E; Mancuso J; Rensvold D; Martinez S; Macias L; Recio-Boiles A; Chandana SR; Mahadevan D
    Expert Opin Investig Drugs; 2019 Aug; 28(8):675-686. PubMed ID: 31327293
    [No Abstract]   [Full Text] [Related]  

  • 23. Innovative design and analysis for rare disease drug development.
    Chow SC; Huang Z
    J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T; Jürges H; Michaeli DT
    BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian Strategies in Rare Diseases.
    Garczarek U; Muehlemann N; Richard F; Yajnik P; Russek-Cohen E
    Ther Innov Regul Sci; 2023 May; 57(3):445-452. PubMed ID: 36566312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use of External Controls in FDA Regulatory Decision Making.
    Jahanshahi M; Gregg K; Davis G; Ndu A; Miller V; Vockley J; Ollivier C; Franolic T; Sakai S
    Ther Innov Regul Sci; 2021 Sep; 55(5):1019-1035. PubMed ID: 34014439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of research collaborations and consortia in rare cancers.
    Blay JY; Coindre JM; Ducimetière F; Ray-Coquard I
    Lancet Oncol; 2016 Feb; 17(2):e62-e69. PubMed ID: 26868355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innovations in Therapy Development for Rare Diseases Through the Rare Disease Cures Accelerator-Data and Analytics Platform.
    Larkindale J; Betourne A; Borens A; Boulanger V; Theurer Crider V; Gavin P; Burton J; Liwski R; Romero K; Walls R; Barrett JS
    Ther Innov Regul Sci; 2022 Sep; 56(5):768-776. PubMed ID: 35668316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():3-21. PubMed ID: 29214563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials.
    Furlong P; Dugar A; White M
    Res Involv Engagem; 2024 Jan; 10(1):1. PubMed ID: 38167117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges in Evaluating Safety and Efficacy in Drug Development for Rare Diseases: A Review for Pharmacists.
    Shah KK; Kogut S; Slitt A
    J Pharm Pract; 2021 Jun; 34(3):472-479. PubMed ID: 32583733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment.
    Applequist J; Burroughs C; Ramirez A; Merkel PA; Rothenberg ME; Trapnell B; Desnick RJ; Sahin M; Krischer JP
    BMC Med Res Methodol; 2020 Mar; 20(1):58. PubMed ID: 32169041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.
    de Blieck EA; Augustine EF; Marshall FJ; Adams H; Cialone J; Dure L; Kwon JM; Newhouse N; Rose K; Rothberg PG; Vierhile A; Mink JW;
    Contemp Clin Trials; 2013 Jul; 35(2):48-54. PubMed ID: 23628560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington's Disease.
    Mullin AP; Corey D; Turner EC; Liwski R; Olson D; Burton J; Sivakumaran S; Hudson LD; Romero K; Stephenson DT; Larkindale J
    Clin Transl Sci; 2021 Jan; 14(1):214-221. PubMed ID: 32702147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The art and science of choosing efficacy endpoints for rare disease clinical trials.
    Cox GF
    Am J Med Genet A; 2018 Apr; 176(4):759-772. PubMed ID: 29423972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets.
    Murthannagari VR; Gonna Nandhi Krishnan G; Manu KV; Jayachandraiah CT; Mandadhi Rajendra PK; Ahmed SS
    Value Health Reg Issues; 2023 May; 35():87-94. PubMed ID: 36921379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.